CD19 and acute lymphoblastic leukemia: One of the main reasons for CAR-T cell therapy failure in solid tumors is the unavailability of solid tumor-specific antigens, unlike in chronic lymphoblast leukemia (CLL) and acute lymphoblast leukemia (ALL), which universally express the antigen CD19 on B cells [4].